Abstract
| Original language | English |
|---|---|
| Pages (from-to) | 264-267 |
| Number of pages | 4 |
| Journal | International Journal of Rheumatic Diseases |
| Volume | 18 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 1 Jan 2015 |
| Externally published | Yes |
Fingerprint
Cite this
}
Biological agents and tuberculosis : Risk estimates and screening strategies. / Dobler, Claudia C.
In: International Journal of Rheumatic Diseases, Vol. 18, No. 3, 01.01.2015, p. 264-267.Research output: Contribution to journal › Article › Research › peer-review
TY - JOUR
T1 - Biological agents and tuberculosis
T2 - Risk estimates and screening strategies
AU - Dobler, Claudia C.
PY - 2015/1/1
Y1 - 2015/1/1
N2 - [Extract] The introduction of biological agents has revolutionized the management of rheumatic diseases. However, the immunomodulatory effect of these drugs is associated with an increased risk of infection, especially an increased risk of tuberculosis (TB) reactivation – a fact of which the medical community has been well aware ever since a study on TB case reports after infliximab therapy was published in 2001. The recognition of an increased risk of TB reactivation in patients on tumor necrosis factor‐alpha (TNF‐α) inhibitor treatment has led to the publication of numerous guidelines on screening and treatment for latent TB infection (LTBI) in these patients, but many uncertainties remain.
AB - [Extract] The introduction of biological agents has revolutionized the management of rheumatic diseases. However, the immunomodulatory effect of these drugs is associated with an increased risk of infection, especially an increased risk of tuberculosis (TB) reactivation – a fact of which the medical community has been well aware ever since a study on TB case reports after infliximab therapy was published in 2001. The recognition of an increased risk of TB reactivation in patients on tumor necrosis factor‐alpha (TNF‐α) inhibitor treatment has led to the publication of numerous guidelines on screening and treatment for latent TB infection (LTBI) in these patients, but many uncertainties remain.
UR - http://www.scopus.com/inward/record.url?scp=84928543341&partnerID=8YFLogxK
U2 - 10.1111/1756-185X.12672
DO - 10.1111/1756-185X.12672
M3 - Article
VL - 18
SP - 264
EP - 267
JO - APLAR Journal of Rheumatology
JF - APLAR Journal of Rheumatology
SN - 1756-1841
IS - 3
ER -